Homepage / Investment / These high-flying life sciences stocks make Netflix and Amazon look dull
Amazon says this Prime Day was its biggest shopping event ever Kudlow says President Trump is 'so dissatisfied' with China trade talks that he is keeping the pressure on As stocks regain their footing, an ominous warning looms Goldman Sachs downgrades Clorox to sell, says valuation is 'unsustainably high' How Satya Nadella has spurred a tripling of Microsoft's stock price in just over four years Kudlow says economic growth could top 4% for 'a quarter or two,' more tax cuts could be coming The one chart that explains Netflix’s stunning comeback US housing starts plunge 12% in June to a nine-month low Aerospace titans Boeing and Airbus top $110 billion in orders at Farnborough Target uses Prime Day to its advantage, logging its 'biggest online shopping day' so far this year Billionaire Marc Lasry sees bitcoin reaching up to $40,000 as it becomes more mainstream and easier to trade These are the 10 US airports where you're most likely to be hacked Amazon shares slightly higher as investors await Prime Day results Wreck of Russian warship found, believed to hold gold worth $130 billion A bullish ‘phenomenon’ in bond market is weeks away from fading, top credit strategist says Stocks making the biggest moves premarket: MS, GOOGL, TXN, UAL, NFLX & more Twitter shares up 50% since late April means most upside priced in, analyst says in downgrade EU fines Google $5 billion over Android antitrust abuse Mortgage applications fall 2.5% as buyers struggle to find affordable homes America may not have the tools to counter the next financial crisis, warn Bernanke, Geithner and Paulson Investors are getting spooked as the risk of a no-deal Brexit rises EU expected to fine Google $5 billion over Android antitrust abuse Ex-FBI chief James Comey urges Americans to vote for Democrats in midterm elections Elon Musk apologizes to British cave diver following baseless 'pedo guy' claim Disney, Comcast and Fox: All you need to know about one of the biggest media battles ever Xiaomi shares notch new high after Hong Kong, mainland China stock exchanges reach agreement The trade war is complicating China's efforts to fix its economy European markets set for a strong open amid earnings; Google in focus Hedge fund billionaire Einhorn places sixth in major poker tournament The biggest spender of political ads on Facebook? President Trump Asian stocks poised to gain after Fed's Powell gives upbeat comments; dollar firmer Stocks are setting up to break to new highs Not all FAANG stocks are created equal EU ruling may be too little, too late to stop Google's mobile dominance Cramer explains how Netflix's stock managed to taper its drop after disappointing on earnings Airbnb condemns New York City's 'bellhop politics,' threatens legal retaliation Amazon sellers say they were unfairly suspended right before Prime Day, and now have two bad choices Investor explains why 'duller' tech stocks can have better returns than 'high-flying' tech names Elon Musk is 'thin-skinned and short-tempered,' says tech VC Texas Instruments CEO Brian Crutcher resigns for violating code of conduct Google Cloud Platform fixes issues that took down Spotify, Snapchat and other popular sites Uber exec: We want to become the 'one stop' transportation app 'What a dumb hearing,' says Democrat as Congress grills tech companies on conservative bias Amazon shares rebound, report says Prime Day sales jumped 89 percent in first 12 hours of the event How to put your medical history on your iPhone in less than 5 minutes Investment chief: Watch these two big events in 2018 Even with Netflix slowing, the market rally is likely not over Cramer: Netflix subscriber weakness debunks the 'sky's the limit' theory on the stock Netflix is looking at watch time as a new area of growth, but the competition is stiff Why Nobel laureate Richard Thaler follows Warren Buffett's advice to avoid bitcoin Rolls-Royce is developing tiny 'cockroach' robots to crawl in and fix airplane engines After Netflix plunge, Wall Street analysts forecast just tame returns ahead for the once high-flying FANG group Roku shares rise after analyst raises streaming video company's price target due to customer growth China is investing 9 times more into Europe than into North America, report reveals Amazon says US Prime Day sales 'so far bigger than ever' as glitch is resolved Netflix is on pace for its worst day in two years US lumber producers see huge opportunity, rush to expand San Francisco to consider tax on companies to help homeless Homebuilder sentiment, still high, stalls as tariffs, labor and land drive up costs Powell backs more rate hikes as economy growing 'considerably stronger' Netflix history is filled with big stock declines – like today – followed by bigger rebounds Intel shares get downgraded by Evercore ISI due to rising competition from Nvidia, AMD Petco aims to reinvent the pet store with something you can't buy online Genetic testing is coming of age, but for consumers it's buyer beware Tech 'FAANG' was the most-crowded trade in the world heading into the Netflix implosion, survey shows Netflix weak subscriber growth may indicate a 'maturity wall' that could whack the stock even more: Analyst This chart may be predicting the bull market's demise Wall Street says Netflix's stock plunge is a ‘compelling’ buying opportunity because the streaming giant ‘never misses twice’ Tesla sinks after Musk tweets, again Boeing announces new division devoted to flying taxis Stocks making the biggest move premarket: NFLX, UNH, GS, AMZN, WMT & more Deutsche Bank downgrades Netflix, but says big subscriber miss is not 'thesis changing' IBM is experimenting with a cryptocurrency that’s pegged to the US dollar North Korea and Zimbabwe: A friendship explained Virgin Galactic spinoff Orbit to launch rockets from the UK with space deal Artificial intelligence will create more jobs than it destroys? That’s what PwC says ‘Treasonous’ Trump and ‘Putin’s poodle:' Scathing headlines follow the Trump-Putin summit China’s fintech companies offer ‘enormous’ opportunity, investment manager says Trump's performance at summit with Putin was 'unprecedented,' experts say Walmart and Microsoft link up on cloud technology as they both battle Amazon European stocks seen mixed amid earnings; Fed’s Powell to address Congress How I knew I should quit my day job and run my start-up full-time: Viral website founder China's stocks have been trounced, but the trade war may ultimately be good news for those shares Billionaire tech investor Peter Thiel bets on crypto start-up Block.one Asian shares subdued open after mixed close on Wall Street; energy stocks under pressure Amazon cloud hits snags after Amazon Prime Day downtime Netflix isn't doomed by one quarter unless people start questioning the long-term investor thesis Tech stocks set to sink on Tuesday after rough evening for ‘FANG’ Netflix plummets after missing big on subscriber growth This wristband lets humans control machines with their minds The U.S. has a rocky history convincing Russia to extradite computer criminals Amazon suffers glitches at the start of Prime Day Jeff Bezos is now the richest man in modern history 'The United States has been foolish': Read Trump and Putin's full exchange Goldman Sachs recommends these 5 highly profitable companies — including Nvidia — to combat rising inflation Goldman Sachs releases 'tactical' stock picks for this earnings season Three red flags for Netflix ahead of its earnings report The bond market may be raising recession fears, but don't expect one anytime soon Cramer: Banks are 'making fortunes' but are still as hated as they were during the financial crisis Putin told Trump at summit: Russia never meddled in US election

Investment

These high-flying life sciences stocks make Netflix and Amazon look dull

The giants of the internet economy are typically cast as the leading fetish objects for growth investors. But compared to the TAMP stocks, FANG looks a bit dull.

What’s TAMP, you ask? That would be Thermo Fisher Scientific, Agilent, Mettler-Toledo and PerkinElmer, just a few of the seldom-discussed names that have powered the obscure S&P 500’s life sciences tools & services subsector to a 41 percent year-to-date gain.

By comparison, FANG – Facebook, Amazon, Netflix and Google parent Alphabet – are up less than 36 percent this year on an equal-weighted basis.

The life sciences tools group — which also includes Illumina, Waters and Quintiles IMS — totals more than $170 billion in market value (about equal to the size of Intel). The companies fall within the health-care sector, but they neither discover cures nor deliver care. They provide lab equipment, testing supplies, analytical devices and services to the pharmaceutical and biotech industries, as well as some chemical and industrial customers.

Part of their appeal to investors in an aging and slow-growing world: They profit from the volume of new-drug investigations and lab tests, favorable demographics and the total amount of health care delivered globally but they don’t have direct regulatory risk from drug-price controls or an Obamacare repeal.

It helps, too, that the companies generally are steady long-term performers that have done many bolt-on acquisitions in their chosen product areas and tend to convert mid-single-digit sales growth into low-double-digit per-share earnings expansion.

A strong and sustained rally in a cluster of stocks will always have a tidy fundamental story behind it, and here’s the case for the lab-products names, according to analyst Paul Knight at Janney Montgomery Scott:

“Even with a sector showing strong performance in 2017, the fundamental backdrop for life science tools is becoming a ‘Goldilocks’ situation. Asia is the largest tools market and growth is in double digits, industrial demand is increasing with robust PMI indicators at seven-year highs, and currency tailwinds are developing.”

S&P 500/Life Sciences Tools & Services versus S&P 500 (YTD)

Source: FactSet

More drug investigations and approved treatments, of increasing complexity, are expected. The booming field of immunotherapy development is a growth engine in itself, requiring complex material-handling and storage processes.

It all nets out to a dream growth-investor arrangement: Long-lived demographic forces, resistance to the economic cycle, stable business-to-business supply relationships, global distribution, and a “razors and blades” recurring-sales model.

The fact that these attributes have propelled such gaudy share-price gains, though, makes it worth asking whether professional investors are crowding into these names to hide from policy or macro threats that might, at some point, fade away.

In the current phase of the bull market, “reliable growth companies” that play a middleman role in de facto oligopolies have hogged a lot of the oxygen, at the expense of more cyclical plays, and especially consumer-facing companies whose moats are seen to be drying up.

Retail, media, branded-clothing and packaged-food stocks are suffering, as investors implicitly shun businesses that require consumers to make an active, conscious decision to spend on a product. Internet platforms, payment processors, aerospace, semiconductors and, yes, health-care tools companies have been enriched at their expense.

The result, for the life-sciences supply names, is valuations at the very high end of the stocks’ own historical range. The TAMP stocks and their peers are now fetching between 20 and 40 times projected earnings for the coming year, compared to around 18 for the broader market. And, remember, these are companies generally growing not much faster than nominal world GDP, with admittedly attractive profit margins.

Technical analysts tend to love the group, identifying what look like sturdy long-term uptrends, even if some appear a bit stretched in the short term (note that the sector shed 1 percent on Tuesday in a largely flat market).

The risk to investors at these prices for the likes of Mettler-Toledo, PerkinElmer or Illumina is not that the companies stumble or laboratory volumes roll over. The stocks, instead, could be exposed to a change in investor preferences and outlook on the world.

If the bull market sputters, of course, it would not be kind to once-sleepy growth stocks at premium multiples. And if, instead, confidence grows in the economic-growth outlook and central banks do allow interest rates to rise, fewer investors might feel the need to hide in this corner of the health-care sector.

The question is not whether these are good businesses. They are. The riddle is always what assumptions motivated the last buyer of the stock of a fine business, and what price might be too high to pay for one.

Source: Investment Cnbc
These high-flying life sciences stocks make Netflix and Amazon look dull

Comments are closed.